Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg)
| Autor: | Flávia Rezende Tinano, Carolina Ramos, Ana Claudia Latronico, Carlos Eduardo Seraphim, Vinicius Nahime Brito, Berenice B. Mendonca, Ana Pinheiro Machado Canton, Aline Guimarães de Faria |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Depot Endocrinology Diabetes and Metabolism Central precocious puberty Urology Puberty Precocious 030209 endocrinology & metabolism Gonadotropin-Releasing Hormone 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Leuprorelin medicine Humans 030212 general & internal medicine Child Retrospective Studies Menarche business.industry Reproduction Bone age Anthropometry medicine.disease Body Height Treatment Outcome Pediatrics Perinatology and Child Health Female Leuprolide business Hormone medicine.drug |
| Zdroj: | Journal of pediatric endocrinologymetabolism : JPEMReferences. 34(11) |
| ISSN: | 2191-0251 |
| Popis: | Objectives Longer-acting gonadotropin-releasing hormone analogs (GnRHa) have been widely used for central precocious puberty (CPP) treatment. However, the follow-up of patients after this treatment are still scarce. Our aim was to describe anthropometric, metabolic, and reproductive follow-up of CPP patients after treatment with leuprorelin acetate 3-month depot (11.25 mg). Methods Twenty-two female patients with idiopathic CPP were treated with leuprorelin acetate 3-month depot (11.25 mg). Their medical records were retrospectively evaluated regarding clinical, hormonal, and imaging aspects before, during, and after GnRHa treatment until adult height (AH). Results At the diagnosis of CPP, the mean chronological age (CA) was 8.2 ± 1.13 year, and mean bone age (BA) was 10.4 ± 1.4 year. Mean height SDS at the start and the end of GnRHa treatment was 1.6 ± 0.8 and 1.3 ± 0.9, respectively. The mean duration of GnRHa treatment was 2.8 ± 0.8 year. Mean predicted adult heights (PAH) at the start and the end of GnRH treatment was 153.2 ± 8.6 and 164.4 ± 7.3 cm, respectively (p0.05). At the AH, the insulin resistance and high LDL levels were identified in 3/17 patients (17.6%) and 2/21 patients (9.5%), respectively. The mean CA of menarche was 12.2 ± 0.5 years. At the AH, PCOS was diagnosed in one patient (4.8%). Conclusions Long-term anthropometric, metabolic, and reproductive follow-up of patients with CPP treated with longer-acting GnRHa revealed effectivity, safety, and favorable outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|